Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

The effect of rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis was a post hoc analysis, therefore results should be interpreted with caution.